Jean-Pierre Valentin
Overview
Explore the profile of Jean-Pierre Valentin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Betat A, Delaunois A, Delpy E, Loiseau M, Maurin A, Poizat G, et al.
Clin Pharmacol Ther
. 2024 May;
116(1):106-116.
PMID: 38709223
The ICH E14/S7B Q&As highlighted the need for best practices concerning the design, execution, analysis, interpretation, and reporting of the in vivo non-rodent QT assay as a component of the...
12.
Bassan A, Steigerwalt R, Keller D, Beilke L, Bradley P, Bringezu F, et al.
Front Toxicol
. 2024 Apr;
6:1370045.
PMID: 38646442
The ICH S1B carcinogenicity global testing guideline has been recently revised with a novel addendum that describes a comprehensive integrated Weight of Evidence (WoE) approach to determine the need for...
13.
Sakata K, Lowe M, Xuan M, Bruffaerts J, Stasi L, Lallemand B, et al.
ACS Med Chem Lett
. 2023 Nov;
14(11):1582-1588.
PMID: 37974949
Plasmepsin X (PMX) has been identified as a multistage antimalarial target. PMX is a malarial aspartyl protease essential for merozoite egress from infected red blood cells and invasion of the...
14.
Rossman E, Wisialowski T, Vargas H, Valentin J, Rolf M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 May;
123:107270.
PMID: 37164235
The ICH E14/S7B Questions and Answers (Q&As) guideline introduces the concept of a "double negative" nonclinical scenario (negative hERG assay and negative in vivo QTc study) to demonstrate that a...
15.
Valentin J, Sibony A, Rosseels M, Delaunois A
J Pharmacol Toxicol Methods
. 2023 May;
123:107269.
PMID: 37149063
This appraisal of state-of-the-art manuscript highlights and expands upon the thoughts conveyed in the lecture of Dr. Jean-Pierre Valentin, recipient of the 2021 Distinguished Service Award of the Safety Pharmacology...
16.
Vargas H, Rossman E, Wisialowski T, Nichols J, Pugsley M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 Mar;
121:107265.
PMID: 36997076
Recent updates and modifications to the clinical ICH E14 and nonclinical ICH S7B guidelines, which both relate to the evaluation of drug-induced delayed repolarization risk, provide an opportunity for nonclinical...
17.
Valentin J, Leishman D
Regul Toxicol Pharmacol
. 2023 Feb;
139:105368.
PMID: 36841350
The ICH S7A guideline on safety pharmacology studies released over 20 years ago largely achieved its objective "to help protect clinical trial participants and patients receiving marketed products from potential...
18.
Cox B, Barton P, Class R, Coxhead H, Delatour C, Gillent E, et al.
Biomater Biosyst
. 2023 Feb;
7:100054.
PMID: 36824483
Human 3D liver microtissues/spheroids are powerful models to study drug-induced liver injury (DILI) but the small number of cells per spheroid limits the models' usefulness to study drug metabolism. In...
19.
Zwickl C, Graham J, Jolly R, Bassan A, Ahlberg E, Amberg A, et al.
Comput Toxicol
. 2023 Feb;
24.
PMID: 36818760
Acute models are being used to support an increasing number of application areas including (1) product research and development, (2) product approval and registration as well as (3) the transport,...
20.
Pognan F, Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, et al.
Nat Rev Drug Discov
. 2023 Feb;
22(4):317-335.
PMID: 36781957
For decades, preclinical toxicology was essentially a descriptive discipline in which treatment-related effects were carefully reported and used as a basis to calculate safety margins for drug candidates. In recent...